# A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

> **NCT02725515** · PHASE2 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** XmAb5871
- **BIOLOGICAL:** Placebo to match XmAb5871

## Key facts

- **NCT ID:** NCT02725515
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-16
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02725515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02725515, "A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02725515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*